Small caps round-up: Lighthouse, Verona Pharma, Manroy...

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved. The firm will officially propose the cancellation at a general meeting on July 31st. If a cancellation is approved, it is expected it will take effect on August 8th.

Shares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved. The firm will officially propose the cancellation at a general meeting on July 31st. If a cancellation is approved, it is expected it will take effect on August 8th.

Verona Pharma, a biotechnology company focused on developing treatments for chronic respiratory diseases, has begun a new trial with its lead drug candidate, RPL554. The trial is designed to test the anti-inflammatory properties of RPL554 in healthy subjects in relation to chronic obstructive pulmonary disease. The trial is a randomised, double-blind, placebo-controlled study that will enrol 24 subjects and is expected to finish around year-end. The trial is the first that is designed to evaluate specifically the anti-inflammatory properties of RPL554 in human subjects.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
MoneyWeek

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.